Boston Scientific Corporation (NYSE:BSX) reported upbeat earnings for the first quarter on Wednesday.

The company posted first-quarter 2026 revenues of $5.20 billion on Wednesday, slightly better than the consensus estimate of $5.17 billion, beating the management guidance of $5.22 billion-$5.31 billion.

The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 79 cents and the management guidance of 78-80 cents.

The company lowered its fiscal 2026 adjusted earnings per share guidance from $3.43-$3.49 to $3.34-$3.41, below the Wall Street estimate of $3.45.

Boston Scientific forecasts net sales growth of approximately 7%-8.5% (prior 10.5%-11.5%) in 2026 on a reported basis, and 6.5%-8% (prior 10%-11%) organically. The company also lowered 2026 sales guidance from $22.18 billion-$22.38 billion to $21.48 billion-$21.78 billion versus the consensus of $22.23 billion.

Boston Scientific shares gained 1.2% to $65.65 in pre-market trading.

These analysts made changes to their price targets on Boston Scientific following earnings announcement.

  • Needham analyst Mike Matson maintained Boston Scientific with a Buy and lowered the price target from $97 to $77.
  • Goldman Sachs analyst David Roman maintained the stock with a Buy and cut the price target from $87 to $84.
  • Baird analyst David Rescott maintained Boston Scientific with an Outperform rating and lowered the price target from $86 to $78.
  • Truist Securities analyst Richard Newitter maintained the stock with a Buy and lowered the price target from $90 to $85.

Considering buying BSX stock? Here’s what analysts think:

Photo via Shutterstock